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Abstract
K63- and Met1-linked ubiquitylation are crucial posttranslational
modifications for TNF receptor signaling. These non-degradative
ubiquitylations are counteracted by deubiquitinases (DUBs), such
as the enzyme CYLD, resulting in an appropriate signal strength,
but the regulation of this process remains incompletely under-
stood. Here, we describe an interaction partner of CYLD, SPATA2,
which we identified by a mass spectrometry screen. We find that
SPATA2 interacts via its PUB domain with CYLD, while a PUB inter-
action motif (PIM) of SPATA2 interacts with the PUB domain of the
LUBAC component HOIP. SPATA2 is required for the recruitment of
CYLD to the TNF receptor signaling complex upon TNFR stimula-
tion. Moreover, SPATA2 acts as an allosteric activator for the K63-
and M1-deubiquitinase activity of CYLD. In consequence, SPATA2
substantially attenuates TNF-induced NF-jB and MAPK signaling.
Conversely, SPATA2 is required for TNF-induced complex II forma-
tion, caspase activation, and apoptosis. Thus, this study identifies
SPATA2 as an important factor in the TNF signaling pathway with
a substantial role for the effects mediated by the cytokine.
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Introduction
Non-degradative ubiquitylation is a crucial posttranslational modifi-
cation for signaling through the TNF receptor 1 (TNFR1). Upon TNF
ligation to its receptor, K63-linked and M1-linked (linear) ubiquity-
lation is mediated by ubiquitin ligases, which are recruited to the
TNFR1 signaling complex (TNF-RSC), such as TRAF2/5, cIAP-1 and
cIAP-2, and LUBAC [1–4]. Upon stimulation of the TNFR1, the
generation of K63-linked ubiquitin chains results in the recruitment
of TAB 2 or TAB 3, and thereby the kinase TAK1, as well as the
LUBAC complex [4–6]. LUBAC is composed of the components
SHARPIN, HOIL-1, and the enzyme HOIP, the latter providing the
E3 Ligase activity. So far, LUBAC is the only known ubiquitin ligase
which is able to generate M1-linked ubiquitin chains [7–9].
Together, K63-linked and linear ubiquitylation of TNF-RSC constitu-
ents creates a platform for the activation of the IKK (IjB kinase)
complex and the MAP kinases like MKK6. These kinases mediate
NF-jB and AP1 transcription factor activation and thereby
inflammatory cytokine expression [10].
The ubiquitylation in the TNF-RSC is counter-regulated by
deubiquitinases (DUBs) such as CYLD, A20, and OTULIN. Thereby,
DUB activity can modify the assembly and the disassembly of the
complex, respectively, and influence the strength and the outcome
of TNFR signaling. Among these DUBs, the deubiquitinase CYLD is
unique, as it has been shown to hydrolyze K63-linked ubiquitin
chains as well as M1-linked ubiquitin chains, thereby attenuating
TNFR-induced NF-jB signaling [11–18].
Upon TNFR1 stimulation, CYLD is recruited to the TNF-RSC by
the LUBAC complex through the interaction with HOIP. This
requires the peptide: N-glycanase/UBA or UBX-containing protein
(PUB) domain of HOIP, but it is not clear whether the interaction of
HOIP and CYLD is direct or not [16]. The M1-specific deubiquitinase
OTULIN also interacts with LUBAC through the HOIP’s PUB domain
[19,20]. However, in contrast to CYLD, OTULIN is not recruited to
the TNF-RSC [16]. In addition, the binding of CYLD and OTULIN to
HOIP was shown to be mutually exclusive, while the reason for this
is not understood [16].
Within hours after TNFR1 stimulation, a second complex, origi-
nating from the TNF-RSC, is forming, termed TNFR complex IIa. This
complex consists of TRADD, RIPK1, FADD, caspase-8, and cFLIP and
can serve as a platform to activate the initiator caspase-8. The protein
cFLIP, which represents a caspase-8 homologue lacking protease
activity, is transcriptionally induced upon intact NF-jB signaling
[21]. cFLIP hetero-dimerizes with caspase-8, thereby preventing
maturation and the pro-apoptotic activity of caspase-8 [22].
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However, an alternative route to TNF-mediated cell death exists,
which is not controlled by NF-jB signaling. Instead, it requires the
kinase activity of RIPK1 and is mediated by a complex termed TNFR
complex IIb, which forms, for example, upon inhibition of cIAP1/2
[23]. RIPK1, in its ubiquitylated form, serves independently of its
kinase activity as a scaffold in complex I. Deubiquitylation of RIPK1
was described to be mediated by CYLD, and this is thought to result
in the formation of complex IIb consisting of RIPK1, FADD, and
caspase-8, mediating caspase-8 activation [11,24]. Thus, in the
context of cell death regulation, the deubiquitinase activity of CYLD
plays a central role, as CYLD was demonstrated to be required for
TNF-induced cell apoptosis and necroptosis [25]. The regulation of
CYLD activity itself within the TNF-RSC, however, remains elusive.
The opposite effect on cell death was observed for the LUBAC
component HOIP. Mice with a homozygous deletion of HOIP exhibit
mid-gestation embryonic lethality, which is mediated by the TNFR1,
and HOIP knockout mouse embryonic fibroblasts (MEFs) are prone
to TNF-induced cell death [26].
The protein SPATA2 (spermatogenesis-associated protein 2) was
initially shown to be highly expressed in testicular Sertoli cells, and
these early reports suggested SPATA2 to play a role in spermatogen-
esis [27,28]. More recently, the Spata2 locus was discussed to be
involved in the predisposition for psoriasis [29,30].
During ongoing studies on the regulation of the activity of CYLD,
we have identified SPATA2 as a CYLD-interacting protein. Here, we
examine how SPATA2 affects TNF-induced signaling processes such
as NF-jB and MAPK activation as well as TNF-mediated cell death.
We show that SPATA2 interacts with CYLD and HOIP, mediating
the recruitment of CYLD to the TNF-RSC. We demonstrate that
SPATA2 enhances the DUB activity of CYLD and that it thereby
attenuates NF-jB and MAPK activation by TNF. Moreover, we show
that SPATA2 is required for TNF-induced cell death.
Results
SPATA2 represents an interaction partner of CYLD
To explore the regulation of CYLD, we performed a SILAC mass
spectrometry experiment, in order to identify novel interaction part-
ners of CYLD, potentially impacting on its regulation. CYLD/
MEFs were infected with retrovirus encoding FLAG-CYLD or were
left uninfected as a control, followed by a labeling of the two dif-
ferent populations with the respective isotopes. The cells were then
treated with TNF, subjected to a FLAG-IP, and after mixing the two
conditions, the CYLD interactome was analyzed (Fig 1A). Among a
number of identified interactors, we found the by far highest heavy/
light ratio for the protein SPATA2 (spermatogenesis-associated
protein 2), identifying it as a promising candidate as a novel interac-
tion partner of CYLD (Fig 1B).
We first aimed at confirming the interaction between CYLD and
SPATA2. Consistent with the results obtained by SILAC-MS, FLAG-
tagged full-length CYLD, expressed in 293T cells, co-immunoprecipi-
tated endogenously expressed SPATA2. The interaction with
SPATA2 was also observed by immunoprecipitation of a FLAG-
tagged C-terminal fragment of CYLD (CYLD 581–956), whereas an
N-terminal fragment of CYLD (CYLD 1–581) did not interact with
SPATA2 (Fig 1C). This interaction was also confirmed using
CYLD/ MEFs expressing FLAG-CYLD. Again, an anti-FLAG anti-
body co-immunoprecipitated endogenous SPATA2 (Fig 1D). The
substantial enrichment of SPATA2 by co-immunoprecipitation with
CYLD is consistent with a high affinity interaction.
In a reverse approach, we expressed FLAG-SPATA2 in 293T cells
and, in line with previous experiments, we were able to detect a
co-immunoprecipitation of endogenous CYLD. A construct lacking
the C-terminal part of SPATA2, but retaining the N-terminus includ-
ing the PUB domain of the protein, co-immunoprecipitated CYLD to
a similar extent. This demonstrated that SPATA2 binds CYLD via
the N-terminal part of SPATA2, which contains the PUB domain of
SPATA2 (Fig 1E).
Together, these data indicate that SPATA2 and CYLD interact via
the C-terminus of CYLD and the N-terminus of SPATA2.
SPATA2 interacts with HOIP and is recruited to the TNF-RSC
The LUBAC component HOIP was recently shown to recruit CYLD
to the TNF-RSC, and the CYLD-HOIP interaction was shown to
require the PUB domain of HOIP, as the N102A or N84A/Y93A PUB
domain mutants of HOIP exhibited a largely reduced interaction
with CYLD [16,31].
As SPATA2 interacts with CYLD, we postulated that SPATA2 is
the bridging factor between CYLD and HOIP. We therefore tested
whether SPATA2 interacts with HOIP. Indeed, we found that FLAG-
HOIP co-immunoprecipitated with SPATA2 (Fig 2A). As shown
previously for CYLD, the interaction of SPATA2 and HOIP also
depended on an intact PUB domain of HOIP, as a PUB domain
mutant, HOIPN102A, exhibited a largely reduced interaction with
SPATA2 (Fig 2A).
The M1-specific deubiquitinase OTULIN, which has been shown
to also interact with the PUB domain of HOIP, requires a PUB inter-
action motif (PIM) for this association [19,20]. We tested the possi-
bility that the interaction of SPATA2 and HOIP also depends on a
PIM in SPATA2. We observed that SPATA2 contains a region with
similarity to the OTULIN PIM and generated a SPATA2 PIM mutant
in analogy to the OTULIN PIM Y56A mutation (which compromises
the interaction of OTULIN with HOIP), by generating a SPATA2Y338A
mutant [19,20]. As shown in Fig 2B, this SPATA2 mutant exhibited
largely reduced binding to HOIP, while the interaction with CYLD
was not affected. Together, these results demonstrate that SPATA2
interacts via a PUB interaction motif (PIM) with the PUB domain of
HOIP.
OTULIN was also found to interact with HOIP through HOIP’s
PUB domain [16,19,20,31,32]. However, the binding of CYLD and
OTULIN to HOIP was shown to be mutually exclusive, and while
CYLD is recruited to the TNF-RSC by HOIP upon TNFR1 ligation,
OTULIN is not [16]. As both SPATA2 and OTULIN interact with
HOIP depending on HOIP’s PUB domain, we asked whether SPATA2
and OTULIN compete for binding to HOIP.
We co-expressed FLAG-tagged HOIP with increasing amounts of
SPATA2. Strikingly, when we analyzed endogenous OTULIN, which
co-immunoprecipitated with HOIP, we found that high expression of
SPATA2 abrogated the binding of OTULIN to HOIP (Fig 2C). This
indicates that it is the competition of SPATA2 and OTULIN, which
underlies the mutual exclusive binding of CYLD and OTULIN to the
LUBAC complex. Consistently, a direct interaction of SPATA2 and
OTULIN did not take place (Fig 2D).
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SPATA2 itself also contains a PUB domain, and we asked
whether this PUB domain contributes to the interaction with CYLD.
In analogy to the HOIP PUB domain N102A mutant, we generated a
SPATA2F108A mutant, which exhibited no detectable binding to
CYLD anymore (Fig 2E). Thus, the PUB domain of SPATA2 is
required for the interaction with CYLD.
Together, these data suggest that SPATA2 is a bridging protein
between HOIP and CYLD. As HOIP recruits CYLD to the TNF-RSC,
A
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Figure 1. Interaction of CYLD and SPATA2.
A Differentially SILAC-labeled CYLD/ cells and CYLD/ cells expressing FLAG-CYLD were treated with mTNF (10 ng/ml). Purified FLAG-CYLD protein complexes were
combined 1:1 and analyzed by LC-MS/MS.
B Heavy/light ratio for ~500 proteins identified in the screen. SPATA2 stands out with a substantially elevated H/L ratio. Each dot represents a protein.
C 293T cells were transfected with empty vector (EV), a vector encoding FLAG-tagged full-length CYLD (wt), or constructs encoding FLAG-tagged CYLD fragments
1–581 (F1) lacking the C-terminus, or 581–956 (F2) lacking the N-terminus, as indicated, followed by FLAG-IP. The blot was probed with antibodies
recognizing SPATA2, FLAG, and tubulin. Endogenous SPATA2 was co-immunoprecipitated to comparable levels by CYLD and the C-terminal CYLD protein
fragment, containing the USP domain.
D CYLD/ MEFs were infected with retrovirus encoding FLAG-CYLD as indicated and CYLD was purified by FLAG-IP. The blot was probed with antibodies recognizing
CYLD, SPATA2, and actin.
E 293T cells were transfected with empty vector (EV), a vector encoding FLAG-tagged full-length SPATA2, or a construct encoding the FLAG-tagged N-terminal part of
SPATA2 (NT), as indicated, followed by FLAG-IP. The blot was probed with antibodies recognizing CYLD, SPATA2, and tubulin. M, marker lane.
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Figure 2. Interaction of HOIP and SPATA2 and recruitment of SPATA2 to the TNF-RSC.
A 293T cells were transfected with a vector encoding V5-tagged full-length SPATA2, along with empty vector (EV), a vector encoding FLAG-tagged HOIP wild-type (wt) or
a vector encoding a FLAG-tagged PUB domain mutant of HOIP (N102A). After FLAG-IP, the blot was probed with antibodies recognizing HOIP, CYLD, V5, and actin.
B 293T cells were transfected with a vector encoding FLAG-tagged HOIP along with either empty vector, V5-tagged SPATA2 (wt) or a V5-tagged PIM mutant of SPATA2
(PIMmut). After V5 IP, the blot was probed with antibodies recognizing FLAG, CYLD, V5, and tubulin.
C 293T cells were transfected with a vector encoding FLAG-tagged HOIP and increasing amounts of V5-tagged SPATA2. After FLAG-IP, the blot was sequentially probed
with antibodies recognizing OTULIN, HOIP, V5, and tubulin.
D 293T cells were transfected with empty vector, FLAG-SPATA2, or FLAG-HOIP. After FLAG-IP, the blot was probed with antibodies recognizing OTULIN, CYLD, FLAG, and actin.
E 293T cells were transfected with empty vector, V5-tagged SPATA2 (wt), or a V5-tagged PUB domain mutant of SPATA2 (PUBmut). After V5 IP, the blot was probed with
antibodies recognizing CYLD, V5 and tubulin.
F A549 cells were treated with FLAG-hTNF (2 lg/ml) for the indicated time. The purified TNF-RSC was sequentially probed with antibodies recognizing SPATA2, CYLD,
RIPK1, TRADD, SHARPIN, TNF, and tubulin as indicated.
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SPATA2 should also be recruited to the TNF-RSC upon TNF stimula-
tion. To test this, we stimulated A549 cells with FLAG-tagged TNF,
followed by FLAG-IP of the receptor complex, at various time
points. We found that SPATA2 was recruited with similar kinetics to
the TNF-RSC as TRADD, RIPK1, SHARPIN, and CYLD (Fig 2F). This
finding identifies SPATA2 as a component of the TNF-RSC.
The recruitment of CYLD to the TNF-RSC requires SPATA2
We further analyzed the role of SPATA2 as a bridging factor of
CYLD and HOIP, by exploring whether it mediates the recruitment
of CYLD to the TNF-RSC, which was previously shown to be HOIP
dependent [16].
To address this question, A549 cells expressing CRISPR/Cas9,
targeting SPATA2, were generated. These cells were treated with
FLAG-tagged TNF, followed by FLAG-IP of the receptor complex at
various time points. As shown in Fig 3A, CYLD recruitment to the
TNF-RSC was compromised to the same extent as the recruitment of
SPATA2 in cells which were infected with CRISPR/Ca9 targeting
SPATA2. This indicated that SPATA2 mediates the interaction
between CYLD and HOIP. Importantly, the recruitment of HOIP and
SHARPIN to the TNF-RSC was not affected upon SPATA2 reduction
(Fig 3A).
Likewise, MEFs lacking SPATA2 were generated by the CRISPR/
Cas9 system, targeting Spata2, and clones with frameshift muta-
tions, incompatible with productive protein expression, on both
Spata2 alleles were selected (Fig EV1A–C). Control cells were gener-
ated using a CRISPR/Cas9 system targeting luciferase. Upon treat-
ment with FLAG-tagged TNF, followed by FLAG-IP of the receptor
complex, CYLD recruitment to the TNF-RSC was increased only in
the presence of SPATA2 corroborating the results we had obtained
with A549 cells (Fig 3B).
Linear ubiquitylation was reported to be the predominant linkage
type in the TNFR signaling pathway [33]. For this reason, and
because CYLD is capable of counteracting M1-linked ubiquitylation,
we specifically asked whether the absence of SPATA2-dependent
recruitment of CYLD to the TNF-RSC results in increased M1-ubiqui-
tylation on the TNF-RSC [14,15]. We tested this possibility using an
antibody which is specific for M1-ubiquitin chains [34]. Indeed,
upon stimulation and isolation of the TNF-RSC with FLAG-HA-
tagged TNF, the complexes from SPATA2 knockout cells exhibited
increased M1-ubiquitylation (Fig 3B).
Taken together, SPATA2 is required for CYLD recruitment to the
TNF-RSC, which was previously shown to depend on HOIP [16].
Along with the finding that SPATA2 interacts with HOIP, dependent
on its PIM, these data indicate that SPATA2 is the bridging factor
between CYLD and HOIP for the recruitment of CYLD to the TNF-RSC.
Thus, in the absence of SPATA2, the loss of CYLD recruitment
results in an increased ubiquitylation of the TNF-RSC. In
consequence, SPATA2 would be expected to attenuate TNF-RSC
signaling.
SPATA2 promotes the M1- and K63-specific DUB activity of CYLD
In principle, the absence of SPATA2, and therefore, the lack of
CYLD recruitment to the TNF-RSC, would explain the increased
M1-ubiquitylation we observed. However, we considered the possi-
bility that the strong direct interaction of SPATA2 and CYLD could
have effects on the enzymatic activity of CYLD. CYLD had been
shown previously to cleave M1- and K63-, but not K48-linked ubiq-
uitin chains [14,15]. We tested this hypothesis in a DUB activity
assay by combining recombinant M1-, K63-, and K48-linked diubiq-
uitin with purified FLAG-CYLD, co-expressed with or without
SPATA2, to assess CYLD DUB activity.
We first retrovirally expressed FLAG-CYLDwt or the inactive
mutant FLAG-CYLDC598A in CYLD/ MEFs. These cells were
infected with retrovirus encoding SPATA2, or control retrovirus.
FLAG-CYLD was isolated by FLAG-IP and, as expected, SPATA2 co-
purified with CYLD. The association did not depend on the enzyme
activity of CYLD, as the inactive mutant FLAG-CYLDC598A also co-
immunoprecipitated SPATA2 (Fig 4A–C). The purified proteins were
then combined with M1-, K63-, or K48-linked diubiquitin substrate.
As expected, and consistent with data from others, wild-type CYLD
mediated proteolysis of the M1- and K63-linked diubiquitin, while
the inactive CYLDC598A mutant did not [14]. When assaying the
A
B
Figure 3. SPATA2-dependent recruitment of CYLD to the TNF-RSC.
A A549 cells were infected to express a CRISPR/Cas9 system targeting
luciferase (as control, indicated wt) or the SPATA2 gene (ko). Mixed cell
cultures were treated with FLAG-hTNF (2 lg/ml) for the indicated time. The
purified TNF-RSC was sequentially probed with antibodies recognizing
SPATA2, CYLD, HOIP, SHARPIN, TRADD, TNF, and tubulin as indicated.
B MEFs were infected to express a CRISPR/Cas9 system targeting luciferase
(wt) or the Spata2 gene (ko). Single clones were generated, which were
treated with FLAG-hTNF (2 lg/ml) for the indicated time. The purified TNF-
RSC was sequentially probed with antibodies recognizing M1-linked
ubiquitin, CYLD, RIPK1, and tubulin as indicated.
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DUB activity of FLAG-CYLD, which had been expressed in the pres-
ence of co-introduced SPATA2, we consistently observed an
increased loss of the band representing diubiquitin, while the band
representing mono-ubiquitin gained intensity (Fig 4A and B). In
contrast, and consistent with previous findings by others, CYLD did
not process K48-linked diubiquitins, and this was not influenced by
the presence or absence of SPATA2 [14,15] (Fig 4C).
Together, these data indicate that SPATA2 is not only required
for CYLD recruitment to the TNF-RSC, but also promotes the M1-
and K63-DUB activity of CYLD, which results in a reduction of
ubiquitylation at the TNF-RSC.
SPATA2 attenuates TNF-induced NF-jB and MAPK activation
Linear and K63-linked ubiquitylation are essential for inflammatory
cytokine signaling and the prevention of TNF-mediated cell death
[7,23,26]. As CYLD has been shown to counteract linear and K63-
linked ubiquitylation [14] and our data demonstrate that SPATA2
and CYLD might cooperate for this function, we explored whether
SPATA2 has an influence on the activation of NF-jB and MAPK
signaling by TNF. To answer this question, MEFs lacking and retain-
ing SPATA2 were generated by use of the CRISPR/Cas9 system and
analyzed for NF-jB and MAPK signaling. Upon treatment with TNF,
SPATA2 knockout cells exhibited accelerated IjBa degradation as
well as increased phosphorylation of p65, IjBa, JNK, p38, and ERK,
as compared to control cells infected with a CRISPR/Cas9 construct
targeting luciferase (Fig 5A).
This effect was also observed in mixed cell cultures (without
generating single clones) expressing lentiCRISPRv2 targeting the
Spata2 gene, ruling out clonal effects as a reason for our observation
[35]. Moreover, similar IjBa degradation as the one shown in
Fig 5A was obtained clones from with different guide RNAs, target-
ing the Spata2 gene (Fig EV2).
SPATA2 (then designated PD1) had been reported to be highly
expressed in testicular Sertoli cells, which are capable of mediating
inflammatory cytokine responses [27,36,37]. We therefore further
investigated the functional role of SPATA2 in this cell type.
To investigate the role of SPATA2 for TNF-RSC-mediated NF-jB
and MAPK activation, we knocked out SPATA2 by CRISPR/Cas9, as
described before, in the 15P-1 Sertoli cell line (Fig EV3). Similar to
the results obtained with MEFs, after stimulation with TNF, SPATA2
knockout cells exhibited increased phosphorylation of IjBa, p65,
JNK, p38, and ERK, as well as accelerated degradation of IjBa
(Fig 5B). Together, our data demonstrate that the loss of SPATA2 to
the TNF-RSC results in increased NF-jB and MAPK signaling, indi-
cating that the recruitment of SPATA2 to the TNF-RSC attenuates
these pathways.
SPATA2 is required for TNF-induced cell death
Ubiquitylation in the TNF-RSC is critical for the prevention of cell
death induced by TNF, as inhibition of K63-linked ubiquitylation
by SMAC mimetics or the absence of linear ubiquitylation in
HOIP-deficient cells entails rapid apoptosis upon TNF receptor
stimulation [2,38–40]. Ubiquitylation in the TNF-RSC is also
crucial for the recruitment of the TAB/TAK1 complex, the
absence of which leads to rapid TNF-induced, RIPK1-dependent
cell death [6,41].
Likewise, TNF-induced cell death in the absence of K63- or
M1-linked ubiquitylation (in cells lacking cIAPs or HOIP), or the
absence of TAK1 kinase activity depends on the enzymatic activ-
ity of RIPK1 [23,26,42].
We chose TAK1-deficient cells [42,43] as a model system for
TNF-induced apoptosis. Using TAK1/ MEFs, or control MEFs, a
SPATA2 knockout was generated by CRISPR/Cas9, targeting the
Spata2 gene as described above (Fig EV1A and D). Upon treatment
with TNF, caspase activity was assessed by probing for cleaved
caspase-3 and PARP in Spata2 wild-type and knockout cells. Strik-
ingly, we found substantially reduced caspase-3 and PARP cleavage
in cells lacking SPATA2. Necrostatin-1 suppressed caspase
A
B
C
Figure 4. SPATA2 promotes CYLD DUB activity.
A–C FLAG-tagged CYLD or catalytically inactive FLAG-CYLD (C598A), respectively,
was stably expressed in CYLD/ MEFs, followed by infection with control
retrovirus, or retrovirus encoding SPATA2, and purified by FLAG-IP. Purified
CYLD or the inactive mutant was added to recombinant diubiquitin for 0,
20, or 40 min at 37°C as indicated. After electrophoresis, the gel was cut
and the lower part was silver-stained to visualize mono- and diubiquitin,
while the upper part was transferred to a membrane and probed for FLAG
and V5. In (A), the experiment was done with M1-linked diubiquitin
substrate; in (B), K63-linked diubiquitin substrate was subjected to the
assay; and in (C), K48-linked diubiquitin substrate was analyzed.
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activation, indicating that the death signal, promoted by SPATA2, is
dependent on RIPK1 activity (Fig 5C).
We also analyzed caspase activity of TAK1/ cells lacking or
retaining SPATA2 after treatment with TNF, using the fluorogenic
substrate DEVD-AMC. Consistent with the Western blot data as
shown in Fig 5C, caspase activity was substantially reduced in cells
lacking SPATA2 (Fig 5D). Likewise, the proportion of apoptotic,
Annexin V-positive cells was substantially reduced in cells deficient
for SPATA2 (Fig 5E). These results suggested that SPATA2 affects
the formation of complex II. Therefore, we performed a FADD
immunoprecipitation to isolate complex II using lysates from
TAK1/ cells lacking or retaining SPATA2 after treatment with
A
C
D E
F
B
Figure 5.
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TNF. We observed an interaction of RIPK1 with FADD in SPATA2
wild-type cells, while in SPATA2 ko cells, the interaction of RIPK1
with FADD was largely reduced, indicating an abrogated formation
of the TNFR complex II (Fig 5F).
Thus, SPATA2 is required for proper complex II formation
induced by TNF. Together, these data show that SPATA2, just like
CYLD, promotes TNF-induced apoptosis, consistent with data previ-
ously reported by others [25].
Discussion
In this study, we identified SPATA2 as a constituent of the TNF-
RSC, with important roles for the activation of both TNF-induced
transcription activation and TNF-induced cell death.
Our finding that SPATA2 interacts with both HOIP and CYLD
suggests the presence of a HOIP-SPATA2-CYLD complex, with
SPATA2 being the bridging factor for the CYLD-HOIP interaction,
which was reported previously by others [16,31,32]. Our data
further show that, upon TNFR1 ligation, SPATA2 and CYLD are
recruited together to the TNF-RSC, along with LUBAC, and that
the recruitment of CYLD (but not LUBAC components) depends
on SPATA2. In consequence, SPATA2 and CYLD recruitment
leads to an attenuation of K63- and M1-ubiquitylation at the
TNF-RSC.
We performed the SILAC-MS analysis, which detected the CYLD-
SPATA2 interaction, upon treatment of the cells with TNF.
However, the interaction data of SPATA2 and CYLD in 293T cells
(in the absence of a TNF-RSC) and data from others, which showed
that CYLD and HOIP interact already in the absence of TNFR stimu-
lation, suggest that a preexisting HOIP-SPATA2-CYLD complex is
recruited to the TNF receptor, upon activation of the receptor [16].
The M1-specific DUB OTULIN has been shown to also interact
with HOIP, while the binding of CYLD and OTULIN to HOIP is
mutually exclusive, and OTULIN is not recruited to the TNF-RSC
[16]. Our data indicate that the competition of the respective PIM
of SPATA2 and OTULIN for binding to the HOIP PUB domain
underlies the mutual exclusive interaction of CYLD and OTULIN
with HOIP.
As both OTULIN and SPATA2 are capable of binding to HOIP,
this capacity alone cannot sufficiently explain the selective recruit-
ment of SPATA and CYLD, but not OTULIN, to the TNF-RSC by
LUBAC. As our data show that HOIP is recruited TNF-RSC in the
absence of SPATA2, a possible explanation would be that the inter-
action of HOIP and OTULIN prevents HOIP from being recruited to
the TNF-RSC.
Our finding that SPATA2 promotes CYLD activity suggests two
ways as to how SPATA2 promotes CYLD activity at the TNF-RSC.
First, SPATA2 recruits CYLD to the TNF-RSC via its direct interac-
tion with HOIP, and secondly, it promotes CYLD activity within the
complex through an allosteric activation of the DUB. This mecha-
nism suggests a role of SPATA2 as an important modulator for
appropriate innate immune signaling. Indeed, our data show that
the loss of SPATA2 substantially promoted NF-jB and MAPK activa-
tion, and, strikingly, the absence of SPATA2 almost completely
abrogated TNF-induced apoptosis.
In initial reports, the most abundant expression of SPATA2 was
observed in Sertoli cells of the testes, leading to the interpretation of
a role of SPATA2 for spermatogenesis. However, while speculative,
our finding that SPATA2 attenuates NF-jB signaling is also compati-
ble with the interpretation that the high expression levels of SPATA2
play a role for the immune privilege of testes. Interestingly, in one
study on CYLD knockout mice, male CYLD/ mice were reported
to be infertile, which was explained by an absence of an early wave
of germ cell apoptosis [11]. We speculate that it is also possible that
unchecked innate immune signaling may have resulted in this
phenotype, and SPATA2 knockout mice will be informative to
further explore this hypothesis.
CYLD had been shown in a shRNA library screen with L929 cells
to be required for apoptosis and necroptosis [25]. It is not clear
how exactly CYLD promotes TNF-induced cell death, and the
molecular mechanism how SPATA2 acts in this context remains to
be determined as well. We show that complex II formation is
compromised in the absence of SPATA2. CYLD had been shown to
deubiquitylate RIPK1, which was suggested to promote TNF-
induced cell death [11,24]. Thus, the cell death-promoting role of
SPATA2, which we have observed, would be compatible with the
enhanced the DUB activity of CYLD, resulting in RIPK1 deubiquity-
lation. However, in agreement with data from others, we find RIPK1
to be ubiquitylated in complex II, indicating that the role RIPK1
ubiquitylation plays for cell death prevention has yet to be clarified
[42,44].
In conclusion, with SPATA2 we have identified a so far unknown
important component in the TNF receptor signaling pathway. Since
it is very likely that this protein plays also a role for other innate
immunity signaling pathways such as TLR or NOD signaling, our
▸Figure 5. SPATA2 attenuates NF-jB and MAPK activation and promotes TNF-induced apoptosis.A MEFs expressing CRISPR/Cas9 targeting luciferase (wt) or single clones generated from MEFs expressing CRISPR/Cas9 targeting the Spata2 gene (ko) were treated with
mTNF (10 ng/ml) as indicated. The blots were probed with antibodies recognizing P-IjBa, IjBa, P-p38, p38, P-JNK, JNK, P-p65, p65, P-ERK, ERK, and tubulin.
B 15P-1 Sertoli cells expressing CRISPR/Cas9 targeting luciferase (as control) or single clones generated from 15P-1 Sertoli cells expressing CRISPR/Cas9 targeting the
Spata2 gene were treated with mTNF (10 ng/ml) as indicated. The blots were probed with antibodies recognizing P-IjBa, IjBa, P-p38, p38, P-JNK, JNK, P-p65, p65, and
tubulin.
C TAK1/ MEFs were infected to express a CRISPR/Cas9 system targeting luciferase or the Spata2 gene, from which single clones were generated. The cells were
treated with mTNF (10 ng/ml) or mTNF along with necrostatin-1 (Nec-1) for 1–3 h as indicated. The blot was sequentially probed with antibodies recognizing PARP,
cleaved caspase-3, and tubulin.
D The same cells as used in (C) were treated as before with TNF (10 ng/ml) or TNF along with necrostatin-1 (Nec-1) for 1 or 2 h as indicated. Caspase activity was
determined using the fluorogenic substrate DEVD-AMC. A representative experiment is shown with error bars (representing SEM) referring to technical replicates.
E Cells from the experiment as shown in (D) were analyzed for apoptosis by Annexin V staining after 2 h. A representative experiment is shown with error bars
(representing SEM) referring to technical replicates.
F Cells as described before were treated with mTNF (10 ng/ml) for the indicated time and lysates were subjected to immunoprecipitation with an anti-FADD antibody.
The immunoprecipitates were subjected to Western blotting and probed for RIPK1, FADD, and actin.
◀
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findings represent an important step toward a deeper understanding
of the regulation of innate immunity.
Materials and Methods
Cell lines
HEK293T (ATCC), CYLD/ MEFs (kindly provided by Ramin
Massoumi, Lund University, Sweden), TAK1/ and control wt
MEFs (kindly provided by Yves Dondelinger and Mathieu Bertrand,
Ghent University, Belgium), A549 (kindly provided by Florian Wein-
berg and Tilman Brummer, Freiburg University, Germany), and
15P-1 Sertoli cells (ATCC) were cultured in DMEM high glucose
medium, supplemented with 10% fetal calf serum and 1% peni-
cillin/streptomycin.
Retroviral transduction of CYLD/ MEFs
To create CYLD/ MEFs stably expressing FLAG-CYLD or the
FLAG-tagged catalytic inactive mutant FLAG-CYLDC598A, 293T cells
were seeded in 78-cm2 culture plates at 20% confluency for trans-
fection to produce retroviral particles. The next day, cells were
transfected with 3 lg pDEST-LTR-N-FLAG-HA-IRESpuro human
FLAG-CYLD wt (Addgene 22544) or pDEST-LTR-N-FLAG-HA-
IRESpuro human FLAG-CYLD C598A (created by using the Quick-
Change site-directed mutagenesis approach; Agilent) together with
3 lg Hit60 [45] and 3 lg pVSV-G (ClonTech) using PEI transfection.
The following day, 5 mM butyrate (Sigma-Aldrich) was added to
enhance expression, which was replaced by 4 ml media in the
evening of the same day. The next day, viral supernatants were
harvested and supplemented with 5 lg/ml polybrene (Sigma-
Aldrich). After filtering the supernatant (0.45 lm), spinfection of
the target cells was performed for 10 min at 400 g. The following
day, selection of the cells was started using 4 lg/ml puromycin
(Sigma-Aldrich) for 4 days. When required, these cells were then
transduced with either a pLXIN control vector (BD Bioscience) or
pLXIN human SPATA2-V5 [subcloned from pcDNA3.1-TOPO
human SPATA2-V5 (vector description see below) in pLXIN vector
(BD Bioscience)] in the same way as described above.
Generation of SPATA2 ko cell lines using lentiviral CRISPR Cas9
In order to generate SPATA2 ko cells, the lentiCRISPRv2 system was
used as described by others [35]. Therefore, three lentiviral vectors
were designed encoding for three different guide RNAs targeting dif-
ferent sequences of exon 1 within the Spata2 gene. As control, a
lentiviral vector was designed encoding for a guide RNA targeting
luciferase sequence (Table 1). The production of lentiviral particles
and subsequent infection and selection of target cells was performed
as described for retroviral transduction above, using lentiviral pack-
aging vectors. In this case 5 lg of lentiCRISPRv2 vector, 1.5 lg
pMISSIONVSV-G (Sigma-Aldrich) and 3 lg pMISSION GAG POL
(Sigma-Aldrich) were transfected using PEI. Infected cells were
selected using 4 lg/ml puromycin for 4 days and mixed cultures
were tested for Cas9 cleavage efficiency and NHEJ repair by
performing a Surveyor assay. To do so, the exon 1 region of the
Spata2 gene was amplified by PCR (primers used: 50: GGCACCAGT
CAGAAGGGTAA; 30: CCAGGATGTCCATTTTGAGC). Then, the
Surveyor assay was performed according to manufacturers’ protocol
(Integrated DNA technologies) to detect mismatches due to muta-
tions, indicating Cas9 nuclease cleavage and repair by NHEJ. Single
cell clones were generated and shifts in the open reading frame
generating a premature STOP codon were verified via sequencing.
Clones with identical deletions on both alleles resulting in a prema-
ture STOP codon were chosen (Figs EV1 and EV3). Control cell lines
transfected with luciferase control vector were used as mixed
cultures. In case of the A549 cell line, mixed cultures were used,
without generating single clones.
Immunoblotting and antibodies
Cells were seeded in 28-cm2 culture plates at 30% confluency 1 day
before treatment. For cell death experiments, cells were treated as
indicated with necrostatin-1 (100 lM, ENZO, 1 h preincubation)
and/or stimulated with mTNF (10 ng/ml, Peprotech) for the indi-
cated time intervals.
Cells were washed before lysis using ice-cold PBS. Cell pellets
were lysed on ice for 5 min using 30–100 ll of lysis buffer [20 mM
Tris–HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 5 mM EDTA, 1×
protease inhibitor cocktail complete (Roche), MG132 (20 lM, Alexis
Biochemicals), phosphatase inhibitor cocktail 1 (1:50, Sigma-
Aldrich)]. Lysates were then centrifuged at 16,100 g for 10 min,
4°C. The supernatants were always kept on ice. Protein concentra-
tion was determined by using the Bradford reagent (Bio-Rad).
Laemmli buffer was added to 40–70 lg of protein lysate and
samples were boiled for 5 min at 95°C. In some cases, the same
amount of lysate was loaded onto more than one gel to allow
sequential probing with several antibodies. Proteins were separated
on SDS–PAGE and transferred to nitrocellulose membranes. To
detect proteins of interest, antibodies (Table 2) were diluted in 3%
milk/TBS–Tween (0.1%).
Immunoprecipitation
For FLAG or V5 immunoprecipitation of FLAG-CYLD and FLAG- or
V5-SPATA2 constructs expressed in 293T cells, the cells were
seeded in 78-cm2 culture plates at 25% confluency. The next day,
cells were transfected with PEI reagent using the following plasmids
(8 lg total DNA amount): pDEST-LTR-N-FLAG-HA-IRESpuro hCYLD
(Addgene), pDEST-LTR-N-FLAG-HA-IRESpuro human CYLD frag-
ment 1–581 (created by using QuickChange site-directed mutagene-
sis approach; Agilent), pDEST-LTR-N-FLAG-HA-IRESpuro human
Table 1. Guide RNAs used for CRISPR/Cas9.
Guide RNA Mouse Spata2 gene Human SPATA2 gene
gRNA#1 ATCAGCCGAAATCGATATAA ATCAGCCGGAATCGATAAAA
gRNA#2 TCAGCCGAAATCGATATAAA CCGGCTGATCCAGTTCTATG
gRNA#3 CGCAGGTACTCATCGCTGCC CGCAGGCACTCATCGCTGCC
Luciferase ACCGCTCCGGCGAAGGCGAA ACCGCTCCGGCGAAGGCGAA
Three different guide RNAs were used to generate CRISPR/Cas9 vectors, each
targeting human or mouse Spata2. As a control, a CRISPR/Cas9 vector
targeting luciferase was generated.
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CYLD fragment 581–956 (created by using QuickChange site-
directed mutagenesis approach; Agilent), control vector pcDNA3.1/
V5-His-TOPO (Invitrogen), pcDNA3.1 FLAG-hSPATA2 and
hSPATA2-V5 were subcloned in pcDNA3.1-TOPO vector after PCR
amplification from vector pF1KM hSPATA2 (Kazusa DNA Res.
Inst.). In addition, for V5 immunoprecipitation the constructs pLXIN
hSPATA2-V5 (subcloned from pcDNA3.1-TOPO human SPATA2-
V5), pLXIN hSPATA2-V5 PIMmut (Y338A), and hSPATA2-V5 PUBmut
(F108A) (created by using QuickChange site-directed mutagenesis
approach; Agilent) were used. Twenty-four hours after transfection,
cells were harvested and lysed in 300–800 ll lysis buffer and protein
concentration was determined as described above. A 30–50 lg
lysate aliquot was taken as input control and the remaining lysate
(adjusted to the same protein concentration among different
samples) was used for IP, rotated for 2 h at 4°C with FLAG M2 affin-
ity gel (30 ll; Sigma-Aldrich) or anti-V5 agarose (30 ll; Sigma-
Aldrich). Beads were washed three times with lysis buffer (see
above). For elution of immune complexes, 30–40 ll lysis buffer
was added to the beads containing either, for FLAG-IP: 3X FLAG
Peptide (150 ng/ll, Sigma-Aldrich) or for V5-IP: V5 peptide (10 lg/ml,
Sigma-Aldrich) followed by incubation for 30 min, 4°C rotating.
Laemmli buffer was added to the eluates and input controls, and
SDS–PAGE analysis was performed as described above.
For FLAG immunoprecipitation of FLAG-CYLD stably expressed
in CYLD/ MEFs, cells were seeded in 78-cm2 culture plates at
40% confluency. The next day, FLAG immunoprecipitation was
performed as described above for transfected 293T cells.
For immunoprecipitation of the TNF-RSC, MEFs or A549 cells
were seeded the day before at 35% confluency in 176-cm2 culture
plates. The next day, cells were stimulated with 2 lg/ml FLAG-HA-
hTNF for the indicated time points. Cells were harvested and lysed
as described above. To lysates of the unstimulated control samples,
0.20 lg/ml FLAG-HA-hTNF was added. Then, FLAG-IP and SDS–
PAGE analysis was performed as described above.
For immunoprecipitation of TNFR complex II, TAK1/ MEFs,
lacking or retaining SPATA2, were seeded the day before at 35%
confluency in 176-cm2 culture plates. The next day, cells were
stimulated with 10 ng/ml mTNF for 30 min or 60 min. Cells were
harvested and lysed as described above. Lysates were incubated
over night with 25 ll A Sepharose CL-4B (GE Healthcare) and 15 ll
of anti-FADD (M-19, Santa Cruz Biotechnology). The next day,
beads were washed three times with lysis buffer and then elution
was performed by adding Laemmli buffer, followed by boiling at
95°C, 5 min. SDS–PAGE analysis was performed as described
above. In some cases, the same amount of lysate was loaded
onto more than one gel to allow sequential probing of several
antibodies.
Cell death assays
For apoptosis quantification by FACS analysis, MEFs were seeded in
duplicates in a 3.8-cm2 culture plate at 30% confluency. The next
day, for RIPK1 inhibition, cells were pretreated for 1 h with necro-
statin-1 (100 lM, ENZO). Then, cells were stimulated with mTNF
(10 ng/ml) for the indicated time points. Cells were harvested and
washed once in Annexin binding buffer (10 mM Hepes, 140 mM
NaCl, 2.5 mM CaCl2, pH 7.4) followed by a staining for 15 min
Table 2. Antibodies used for Western blotting.
Antibody Dilution Product no. Supplier
SPATA2 1:1,000 ARP59151_P050 BIOZOL
SPATA2 1:1,000 A302-493A Bethyl
Laboratories
FLAG M2 1:5,000 Monoclonal,
F1804
Sigma
Tubulin 1:5,000 alpha clone
YL1/2, MCA77G
AbDseroTEC
CYLD 1:1,000 D1A10, #8462 Cell Signaling
Technology
Actin 1:20,000 #691000 MP Biomedicals
HOIP/RNF31 1:1,000 clone #875227,
MAB8039
R&D systems
HOIP/RNF31 1:1,000 A303-560A Bethyl
Laboratories
V5 1:5,000 R960-25 Invitrogen
P-IjBa 1:1,000 14D4, #2859 Cell Signaling
Technology
IjBa 1:500 C21, sc-371 Santa Cruz
Biotechnology
P-p38 1:1,000 Thr180/Tyr182,
D3F9, #4511
Cell Signaling
Technology
p38 1:1,000 L53F8, #9228 Cell Signaling
Technology
P-p65 1:1,000 S536, #3031 Cell Signaling
Technology
p65 1:1,000 L8F6, #6965 Cell Signaling
Technology
P-ERK 1:2,000 Thyr202/204,
#9101
Cell Signaling
Technology
ERK 1:400 K23, sc-94 Santa Cruz
Biotechnology
P-JNK 1:1,000 Thr183/Tyr185,
#9251
Cell Signaling
Technology
JNK 1:1,000 #9252 Cell Signaling
Technology
PARP 1:1,000 #9542 Cell Signaling
Technology
cl. caspase-3 1:1,000 Asp175, # 9661 Cell Signaling
Technology
OTULIN 1:300 ab151117 Abcam
TNFa 1:200 H-156, sc-8301 Santa Cruz
Biotechnology
SHARPIN 1:1,000 14626-1-AP Proteintech
TRADD 1:400 H278, sc-7868 Santa Cruz
Biotechnology
M1-Ubi 1:1,000 1F11/3F5/Y102L Genentech
RIPK1 1:1,000 D94C12, #3493 Cell Signaling
Technology
FADD 1:1,000 1F7, ADI-AAM-
212-E
ENZO
FADD 15 ll for IP M19, sc-6036 Santa Cruz
Biotechnology
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within the same buffer using Alexa Fluor 647 Annexin V (Bio
Legend, 200 ng/ml final concentration) in the dark. The fraction of
Annexin V-positive cells was measured using a FACSCalibur (BD
Bioscience).
Caspase-3 activity was measured by incubating whole cell lysates
(20 lg in a volume of max. 40 ll) in duplicates with fluorogenic
DEVD-AMC (60 lM, Enzo Life Science), adjusted to a final volume
of 100 ll by adding caspase activity buffer (100 mM Hepes, pH 7.5,
10 mM DTT). When the substrate was added, fluorescence was
measured immediately at 37°C for 30 min with a time interval of
2 min (Tecan Infinite M200 microplate reader). The slope of the
linear regression was calculated to state the relative caspase activity.
DUB activity assay
To analyze CYLD catalytic activity dependent on SPATA2, CYLD/
MEFs were used stably expressing FLAG-CYLD wt, or the catalytic
inactive mutant C598A, respectively. These cells were each infected
with retrovirus encoding SPATA2-V5 or empty vector, as described
above. Cells were seeded in 176-cm2 culture plates at 25% conflu-
ency. The next day, cells were harvested and FLAG-IP and elution
was performed as described above, with the exception that the
beads were washed after FLAG-IP as follows: one time washed with
lysis buffer (see above), 2 times washed with PBS (adjusted to
400 mM NaCl), one time with PBS (150 mM NaCl) and in a final
step with lysis buffer. Then, 10 ll eluate for each time point (0, 20,
40 min; 37°C) was incubated together with 1.5 ll 10× DUB buffer
(500 mM NaCl, 500 mM Tris pH 7.4, 50 mM DTT) [46] and 100 ng
diubiquitin (Ubiqbio) adjusted to a final volume of 15 ll using lysis
buffer containing fresh protease inhibitors. The reaction was
stopped by adding Laemmli buffer to the samples. Samples were
run on a NuPage Novex 4–12% Bis-Tris protein gel using the corre-
sponding NuPage MES SDS Running Buffer (Thermo Fisher Scien-
tific). Ubiquitin cleavage was detected by silver staining (performed
according to protocol, using SilverQuestTM Silver Staining kit, Life
Technologies). Before silver staining, the upper half of the gel was
cut and transferred to a membrane in order to probe with antibodies
recognizing FLAG (CYLD) and V5 (SPATA2).
Mass spectrometry analysis
CYLD/ MEFs and CYLD/ MEFs stably expressing FLAG-CYLD
wt were labeled for six cell doublings with either “light”: L-arginine
and L-lysine (Arg0/Lys0), or “heavy”: L-arginine-13C6-
14N4 and
L-lysine-2H4 (Arg6/Lys4) SILAC DMEM media. SILAC-labeled cells
were expanded up to two 176-cm2 culture plates at 60% confluency
for each cell type. Cells were treated with mTNF (20 ng/ml) for
20 min. After stimulation, cells were harvested (two plates of each
condition were pooled) and lysed in 1 ml lysis buffer (see above),
followed by FLAG immunoprecipitation as described above. Beads
were washed three times using lysis buffer. In the final wash step,
the beads of both conditions were combined and protein complexes
were eluted by adding Laemmli buffer (containing 50 mM DTT)
diluted in lysis buffer. For MS sample preparation and measure-
ments, samples were prepared with 1 mM DTT for 5 min at 95°C
and alkylated using 5.5 mM iodoacetamide for 30 min at 25°C.
Protein mixtures were separated by SDS–PAGE (4–12% Bis-Tris
mini gradient gel) and gel lanes were cut into 10 equal slices. Gel
fractions were in-gel digested using trypsin (Promega) [47]. Digests
were performed overnight at 37°C in 0.05 M NH4HCO3 (pH 8).
About 0.1 lg of protease was used for each gel band. Peptides were
extracted from the gel slices with ethanol and resulting peptide
mixtures were processed on STAGE tips as described [48].
Samples analyzed by MS were measured on LTQ Orbitrap XL
mass spectrometer (Thermo Fisher Scientific) coupled either to an
Agilent 1200 nanoflow HPLC (Agilent Technologies) or an Eksigent
NanoLC-ultra. HPLC-column tips (fused silica) with 75 lm inner
diameter were self-packed with Reprosil-Pur 120 ODS-3 to a length
of 20 cm. No pre-column was used. Peptides were injected at a
flow of 500 nl/min in 92% buffer A (0.5% acetic acid in HPLC
gradient grade water) and 2% buffer B (0.5% acetic acid in 80%
acetonitrile, 20% water). Separation was achieved by a linear
gradient from 10 to 30% of buffer B at a flow rate of 250 nl/min.
The mass spectrometer was operated in the data-dependent mode
and switched automatically between MS (max. of 1 × 10 ions) and
MS/MS. Each MS scan was followed by a maximum of five MS/MS
scans in the linear ion trap using normalized collision energy of
35% and a target value of 5,000. Parent ions with a charge states
of z = 1 and unassigned charge states were excluded from fragmen-
tation. The mass range for MS was m/z = 370–2,000. The resolu-
tion was set to 60,000. MS parameters were as follows: spray
voltage 2.3 kV; no sheath and auxiliary gas flow; ion transfer tube
temperature 125°C.
Software Xcalibur (Thermo Scientific) and Mascot Daemon
version 2.4.0 (Matrix Science) were used for data acquisition and
processing.
Expanded View for this article is available online.
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